Figure 3
From: AXL inhibition improves BRAF-targeted treatment in melanoma
Melanoma cells show reduced cell viability following combined inhibition of AXL and BRAF. (a) The level of AXL (detected by flow cytometry) in nine melanoma cell lines. (b, c) Cell viability of three AXLhigh melanoma cell lines treated with different concentrations, as indicated, of AXLi (b) or 2 µM BRAFi, 1 µM AXLi (for Melmet 1), 2 µM AXLi (for A375), 3 µM AXLi (for WM1366) or a combination of both drugs (c) for 24 or 72 h. The treatment effect was scored by CTG assay and presented as % relative to the respective non-treated controls set to 100%. Average ± SEM, n = 3. *p ≤ 0.05; **p ≤ 0.01; and ***p ≤ 0.001.
